Skip to main content
Premium Trial:

Request an Annual Quote

Tempus, University of Chicago Medicine Partner on Pancreatic Cancer Study

NEW YORK (GenomeWeb) – Tempus and University of Chicago Medicine announced today that they have partnered to study clinical and molecular data from pancreatic cancer patients in order to improve the prediction of treatment responses.

Under the terms of their alliance, Tempus will combine information from its own database with genomic data, biospecimens, and clinical information from more than 300 pancreatic cancer patients collected by the university's Chicago Pancreatic Cancer Initiative (CPCI). The company will then use bioinformatics and machine learning to analyze these data, as well as to generate additional genomic data using its technologies.

Additional terms were not disclosed.

"The University of Chicago and Tempus share a commitment to accelerate pancreatic cancer research and identify treatments that can improve the lives of those diagnosed," CPCI researcher and Tempus collaborator Ralph Weichselbaum said in a statement. "We are optimistic that this collaboration can make a difference in the lives of those diagnosed and treated for pancreatic cancer."

Earlier this month, Tempus formed a similar alliance with the University of Michigan focused on breast cancer. And in March, Tempus partnered with the University of Chicago Medicine to perform molecular sequencing on about 1,000 breast cancer patients.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.